Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NeoART - A Phase Ib/II Platform Trial Evaluating the Safety and Activity of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma

NCT06731803 is registered in ClinicalTrials.gov with Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest as lead sponsor.

NCT NCT06731803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06731803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NeoART - A Phase Ib/II Platform Trial Evaluating the Safety and Activity of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 25, 2025
Completion date
December 31, 2027
Enrollment
36 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

esophagogastric adenocarcinoma